Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03857542 · ClinicalTrials.gov registry record · Phase 3
A Phase 3 Efficacy Study of Pilocarpine HCl Ophthalmic Solution (AGN-190584) in Participants With Presbyopia
A Phase 3 study, sponsored by Allergan.
- Completed
- Registry status
- Phase 3
- Development phase
- 427
- Enrollment target
NCT03857542 is a Phase 3 study that has completed, run by Allergan. The registered enrollment target is 427 participants.
The verdict
NCT03857542, a Phase 3 study, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 427 participants
- Enrollment target
Study Summary
This clinical study will evaluate pilocarpine hydrogen chloride (HCl) ophthalmic solution (AGN-190584) in an expanded participant population to establish efficacy, safety, and tolerability versus the vehicle-control when administered, over a 30-day study intervention period, once daily bilaterally in participants with presbyopia.
Interventions
- OTHER Vehicle
- DRUG Pilocarpine HCl Ophthalmic Solution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 427 participants |
| Start Date | 2019-03-01 |
| Est. Completion | 2020-09-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03857542
The ClinicalTrials.gov registry entry for NCT03857542 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 427 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Allergan, which has 314 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Vehicle is the first listed.
NCT03857542 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03857542 about?
NCT03857542 is a clinical study titled "A Phase 3 Efficacy Study of Pilocarpine HCl Ophthalmic Solution (AGN-190584) in Participants With Presbyopia". This clinical study will evaluate pilocarpine hydrogen chloride (HCl) ophthalmic solution (AGN-190584) in an expanded participant population to establish efficacy, safety, and tolerability versus the vehicle-control when administered, over a 30-day study intervention period, once daily bilaterally i...
What is the current status of trial NCT03857542?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 427 participants. The study started on 2019-03-01. Estimated completion is 2020-09-10.
What interventions are being tested in trial NCT03857542?
The interventions under investigation include: Vehicle (OTHER), Pilocarpine HCl Ophthalmic Solution (DRUG).
Who is sponsoring clinical trial NCT03857542?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.